Recent FDA approvals of new PET radiotracers and therapeutic approaches for high-prevalence diseases, such as prostate cancer and Alzheimer's Disease, emphasize the need for reliable and comprehensive ...

GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...

GE HealthCare has secured the FDA’s approval for an injectable, radioactive imaging agent that gives clinicians a clearer picture into blocked arteries in the heart and any damage to cardiac tissue.

Stanford (Calif.) Medicine has renewed its research partnership with GE HealthCare to develop new clinical pathways and imaging solutions through the use of total-body PET/CT. Through their ...

Flourish Research ® today announced a strategic partnership with Capitol Imaging Services in advance of the launch of Flourish Imaging™, an advanced imaging center currently under development in ...

GE HealthCare and the Department of Radiology at Stanford Medicine aim to explore total body positron emission tomography/computed tomography (PET/CT) technology for new clinical pathways to help ...

The FDA has approved an updated label for Vizamyl (flutemetamol F 18 injection), including quantification which enables a more continuous and objective measure of amyloid in the brain This approval ...

The U.S. FDA has granted 510(k) clearance to GE Healthcare Technologies Inc. for its Precision DL for PET/CT, an artificial intelligence (AI) and deep learning (DL)-powered software designed to ...

CHICAGO--(BUSINESS WIRE)--GE HealthCare is set to unveil SIGNA PET/MR AIR i, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting. The company will showcase the ...